Patients
Novartis is committed to creating value for all patients — including those who cannot afford treatment. In 2009, our access-to-medicine programs, valued at USD 1.5 billion, reached 79.5 million patients around the world.
Some of the key measures Novartis is taking to put patients first:
- Working with the World Health Organization to help eliminate leprosy by offering free treatment to patients worldwide
- Supplying our antimalarial drug Coartem without profit through multilateral institutions and public-private partnerships
- Developing medicines to combat tropical, infectious diseases such as dengue, tuberculosis and malaria through the Novartis Institute for Tropical Diseases
Learn more about the Novartis Institute for Tropical Diseases
- Researching vaccines for diseases of the developing world through the Novartis Vaccines Institute for Global Health
Learn more about the Novartis Vaccines Institute for Global Health
- Providing discounts and assistance programs to low-income patients in the developed world, including a patient assistance program for the cancer therapy Gleevec/Glivec — one of the most far-reaching patient-assistance programs ever implemented on a global scale — ensuring access for all patients who cannot afford it
Learn more about Gleevec/Glivec (Intended for US residents only)
Learn more on our corporate citizenship website
Patient groups
Our commitment to high-quality healthcare has led to partnerships between Novartis and patient groups.
Novartis Foundation for Sustainable Development
The Novartis Foundation for Sustainable Development works to improve quality of life in developing countries.
